Alecensa 150mg Capsule
PDF Leaflet Revision Date: 25 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for ALK-positive NSCLC.
Dosage (summary)
600 mg orally twice daily; 450 mg for severe hepatic impairment.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A substrates
- P-gp substrates
Contraindications
- Hypersensitivity to alectinib
- Pregnancy
- Lactation
Common side effects
- Constipation
- Oedema
- Myalgia
- Nausea
- Increased bilirubin
- Anaemia
- Rash
Counselling Points
- Take with food
- Avoid sun exposure
- Use effective contraception during treatment
Serious warnings
- Interstitial lung disease
- Hepatotoxicity
- Severe myalgia
- Bradycardia
- Haemolytic anaemia
Important Disclaimer
The Alecensa 150mg Capsule professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
